Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024

Read More

Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer

May 8, 2024

Read More

Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting

April 24, 2024

Read More

We are pioneers in cell and gene therapy

Leading the next generation of engineered therapeutics

Our Platform

Our proprietary
cytoDRiVE platform

Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule

Read More


Join Our Team

Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.


Read More